Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OPC-51803是一种可口服的非肽加压素(AVP)V(2)受体选择性激动剂,可用于治疗尿失禁和夜尿。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,350 | 现货 | ||
5 mg | ¥ 5,630 | 现货 | ||
10 mg | ¥ 7,790 | 现货 | ||
25 mg | ¥ 11,200 | 现货 | ||
50 mg | ¥ 13,800 | 现货 | ||
100 mg | ¥ 17,500 | 现货 | ||
500 mg | ¥ 34,800 | 现货 |
产品描述 | OPC-51803 is an orally available nonapeptidylpressor (AVP) V(2) receptor selective agonist for the treatment of urinary incontinence and nocturia. |
靶点活性 | V2 receptor:91.9+10.8 nM(Ki), cAMP:189+/-14 nM(EC50), V2 receptor:189+14 Nm(EC50), V1a receptor:819+39 nM(Ki) |
体外活性 |
OPC-51803 and dDAVP displaced [(3)H]-AVP binding to human V(2)- and V(1a)-receptors with K(i) values of 91.9+/-10.8 nM (n = 6) and 3.12+/-0.38 nM (n = 6) for V(2)-receptors, and 819+/-39 nM (n = 6) and 41.5+/-9.9 nM (n = 6) for V(1a)-receptors, indicating that OPC-51803 was about nine times more selective for V(2)-receptors, similar to the selectivity of dDAVP.[5] OPC-51803 concentration-dependently increased cyclic adenosine 3', 5'-monophosphate (cyclic AMP) production in HeLa cells expressing human V(2)-receptors with an EC(50) value of 189+/-14 nM (n = 6).[5] |
体内活性 |
OPC-51803 shows antidiuretic action in dogs. OPC-51803 (0.03 to 0.3 mg/kg; oral) decreased urine volume and increased urinary osmolality in a dose-dependent manner in water-loaded dogs.[4] OPC-51803 infusions (0.3 and 3 microg x kg(-1) x min(-1); Intravenous ) did not affect renal or systemic hemodynamics in anesthetized dogs.[4] |
别名 | SOU-003, SOU 003, SOU003, OPC51803, OPC 51803 |
分子量 | 454 |
分子式 | C26H32ClN3O2 |
CAS No. | 192514-54-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (99.12 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2026 mL | 11.0132 mL | 22.0264 mL | 55.0661 mL |
5 mM | 0.4405 mL | 2.2026 mL | 4.4053 mL | 11.0132 mL | |
10 mM | 0.2203 mL | 1.1013 mL | 2.2026 mL | 5.5066 mL | |
20 mM | 0.1101 mL | 0.5507 mL | 1.1013 mL | 2.7533 mL | |
50 mM | 0.0441 mL | 0.2203 mL | 0.4405 mL | 1.1013 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
OPC-51803 192514-54-8 GPCR/G Protein Vasopressin Receptor SOU-003 SOU 003 SOU003 OPC51803 OPC 51803 Inhibitor inhibitor inhibit